Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII ® (aripiprazole) ...

ABILIFY extended–release injectable suspension, for intramuscular use, is administered to the patient just once every four weeks. It first became available to patients in the US in March 2013 and is ...

Aristada (aripiprazole lauroxil) is a prescription drug that’s used to treat schizophrenia. Aristada is given by a healthcare professional as an injection into a muscle. Aristada is used as a ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...

November 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for the oral formulation of aripiprazole (Abilify tablets, orally disintegrating tablets, and oral ...